To access a multimedia version of this release, please visit:
LAVAL, QC, Nov. 29, 2011 /CNW Telbec/ - As Diabetes Awareness Month
closes, Diabète Québec and Sanofi Canada are proud to work in
partnership to raise awareness for and celebrate the contribution of
diabetes innovation throughout the past 90 years. Today at Alexis
Nihon Plaza the public was invited to a special historical display of
those diabetes innovations that have helped thousands of people with
diabetes live life to the fullest.
One of Canada's major innovations was the large-scale production of
insulin. About 90 years ago, in Toronto, at the Connaught Laboratories,
production methods were developed and perfected by Dr. John G.
Fitzgerald (1882-1940) and his associates. Their breakthrough made
insulin available on a mass scale and at affordable prices for the
first time, within a year after its discovery. For more information,
please click here.
"Our involvement in diabetes management goes back to the early 20th century when, following the discovery of insulin in Canada by Frederick
Banting and Charles Best, we played a key role in developing techniques
for the large-scale production of insulin. We are incredibly proud of
our history," said Mark Lievonen, President of Sanofi Pasteur Limited.
As part of the celebration, Montreal cake designer, Tim Rivard, unveiled
a specially-designed cake for the occasion. Even when living with
diabetes, sugars can be included in a healthy diet as a part of a
carefully planned meal plan. Diabetes Québec also had an information
booth and nutritionist to educate people about diabetes prevention and
maintaining a healthy lifestyle.
"Early this century, type 1 diabetes was a death sentence. Thanks to the
discovery and manufacturing of insulin, people with diabetes from
around the world now live longer and healthier lives. It is important
to celebrate our successes in managing diabetes because every day is a
new challenge," said Serge Langlois, President and Executive Director
at Diabetes Québec.
"Diabetes affects millions of Canadians so every innovation, whether a
breakthrough or incremental, is important - and we have a rich history
here to celebrate," said Hugh O'Neill, President and CEO of Sanofi
Canada. "At Sanofi Canada, our focus is to simplify the management of
a complex disease and we are working hard in partnership with everyone
committed to diabetes care, developing innovative solutions to help
people with diabetes live as people not as patients."
Currently, there are 9 million people living with diabetes or
prediabetes in Canada. Diabetes is a chronic condition that stems from
the body's inability to sufficiently produce and/or properly use
insulin which the body needs to use sugar as an energy source. There
are three main types of diabetes: type 1, where the body makes little
or no insulin; type 2, where the body makes insulin but cannot use it
properly; and gestational diabetes, where the body is not able to
properly use insulin during pregnancy. This type of diabetes could go
away after the baby is born.
Diabetes is both a national and an international challenge. By 2020, it
is estimated that diabetes will cost the Canadian healthcare system
$16.9 billion a year. Currently, one in four Canadians lives with
diabetes, undiagnosed diabetes, or prediabetes; this will rise to one
in three by 2020 if current trends continue.
Left untreated or improperly managed, diabetes can result in a variety
of complications, including: heart disease; kidney disease; eye
disease; problems with erection (impotence) and nerve damage. The first
step in preventing or delaying the onset of these complications is
recognizing the risk factors, as well as the signs and symptoms of
About Diabetes Quebec
For more than 50 years, Diabetes Québec has been informing the Quebec
public about the disease and raising awareness of diabetes. This
insidious disease now affects more than 760,000 Quebecers with 40,000
new cases of diabetes diagnosed each year. Its incidence has been
rising at an epidemic rate and is taking a heavy economic toll. The
province now spends more than $3 billion a year in direct and indirect
healthcare costs related to this disease. To learn more, visit www.diabete.qc.ca.
Sanofi, a global and diversified healthcare leader, discovers, develops
and distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven growth
platforms: diabetes solutions, human vaccines, innovative drugs, rare
diseases, consumer healthcare, emerging markets and animal health.
Sanofi is represented in Canada by the pharmaceutical company
sanofi-aventis Canada Inc., based in Laval, Quebec, and by the vaccines
company Sanofi Pasteur Limited, based in Toronto, Ontario. Together
they employ more than 2,000 people across the country. With combined
R&D investments of $159.2 million in 2010, they are leaders in Canada's
biopharmaceutical sector, a critical knowledge-based industry that
generates jobs, business and opportunity throughout the country.
Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward-looking statements are
generally identified by the words "expects", "anticipates", "believes",
"intends", "estimates", "plans" and similar expressions. Although
Sanofi's management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied
or projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when to
approve any drug, device or biological application that may be filed
for any such product candidates as well as their decisions regarding
labeling and other matters that could affect the availability or
commercial potential of such products candidates, the absence of
guarantee that the products candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities as well as those discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those listed
under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for
the year ended December 31, 2010. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
1 Canadian Diabetes Association, 2011. Sweeteners. Available at http://www.diabetes.ca/diabetes-and-you/nutrition/sweeteners/ [Accessed 14 November 2011].
SOURCE Sanofi Canada
For further information: